Tadocizumab

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research[1][2].

Product Specifications

CAS Number

[339086-80-5]

Product Name Alternative

C4G1; YM-337

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/tadocizumab.html

Purity

Solubility

10 mM in DMSO

Smiles

[Tadocizumab]

References & Citations

[1]S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75 (4) :679-84.|[2]Ken-ichi Suzuki, et al. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol Pharm Bull. 2002 Aug;25 (8) :1006-12.